Is acetyl tetrapeptide-5 FDA-approved, and what does the research show?

What is acetyl tetrapeptide-5?

Acetyl tetrapeptide-5 is a synthetic peptide, a short chain of four amino acids made in a laboratory; its name says it carries an acetyl group ²,¹⁰. Lipotec introduced it under the trade name Eyeseryl, and Lubrizol listed it in November 2025 as Eyeseryl peptide solution G, a solution of the peptide in glycerin and water ¹¹,¹.

The maker calls it a "tetrapeptide with anti-oedema properties," edema being fluid swelling, for products where "a reduction of puffiness under the eyes is desired" ². It appears in eye serums and other eye products from several brands, often beside other peptides ⁹. A 2026 safety-framework paper on cosmetic peptides lists it in two mechanism classes at once and does not say which applies ¹⁰.

Is acetyl tetrapeptide-5 FDA-approved?

No, and no cosmetic ingredient other than a color additive is approved by FDA before sale. FDA's own page on its authority over cosmetics, current as of November 18, 2025, states that "cosmetic products and ingredients do not need FDA premarket approval, with the exception of color additives" ³. The duty of safety sits with the maker and the seller, who "have a legal responsibility to ensure the safety of their products" ³. The law does not oblige them to share their safety data with FDA ³. Nor is it approved as a drug: Drugs@FDA lists no approved acetyl tetrapeptide-5 product as of November 9, 2026 ⁴.

The line between a cosmetic and a drug is intended use, which FDA reads from the claims on the label, in advertising and in other promotion ¹². Under the law, an article other than food "intended to affect the structure or any function of the body" is a drug ¹². FDA's page on anti-aging products, current as of February 25, 2022, says a product meant "to make lines and wrinkles less noticeable, simply by moisturizing the skin" is a cosmetic ¹³. A product meant "to remove wrinkles or increase the skin's production of collagen" falls on the other side, as "a drug or a medical device" ¹³. FDA has not written about this ingredient or the under-eye claim in any page cited here ³,¹²,¹³,¹⁴.

MoCRA, the Modernization of Cosmetics Regulation Act of 2022, added to FDA's powers over cosmetics ¹⁴. Where FDA finds "a reasonable probability that a cosmetic is adulterated or misbranded" and that its use "will cause serious adverse health consequences or death," it can order a recall "if the responsible person refuses to do so voluntarily" ¹⁴. The company responsible for a cosmetic must report a serious adverse event to FDA within 15 business days ¹⁴.

The Cosmetic Ingredient Review, or CIR, is an expert panel paid for by the cosmetics industry's trade association; CIR says it and its panel are independent of the industry ¹⁵. No released assessment of acetyl tetrapeptide-5 by that panel could be found on November 10, 2026. A 2026 safety-framework paper by Procter & Gamble scientists lists the peptides the panel has assessed, and this one is not among them ¹⁰.

See the FDA status of every peptide, updated weekly.

How does acetyl tetrapeptide-5 work?

The draining mechanism is the maker's proposal, from its own laboratory tests. Lipotec's brochure reports two laboratory results ². In a test on endothelial cells, the cells that line blood vessels, the peptide "is able to inhibit vascular permeability in a dose-dependent manner," meaning more peptide gave more effect ². In a chemical model of glycation, the reaction in which sugars bind to proteins such as collagen and stiffen them, it slowed the reaction ².

From these the maker claims a "draining and decongesting effect" against the fluid that collects under the eyes ². The brochure is the company's own, with no peer review.

A 2022 review, written under an educational grant from RELIFE S.r.l., states that the peptide inhibits angiotensin-converting enzyme ¹⁶. That enzyme is part of the body's blood-pressure and fluid control. The review says inhibiting it drains the area around the eyes ¹⁶. The review cites a 2017 review for that statement, not an experiment ¹⁶.

A 2021 cell study used the enzyme's activity as its measure of the peptide's effect ⁸. No source opened measures how much of the peptide passes through intact skin.

What does the research show?

No published trial of acetyl tetrapeptide-5 on its own was found in a PubMed search on November 10, 2026. The one PubMed record that names it is a cell study ⁸. The human evidence for the ingredient alone is the maker's, in its brochure and a news release, and is unpublished ²,¹¹.

The maker's brochure reports its own tests as follows ². In a 60-day test, 20 women aged 18 to 65 applied a cream with 10 percent of the Eyeseryl solution under the eyes twice a day ². A dermatologist graded their eye bags ². The solution itself holds 0.1 percent of the peptide ². In a 28-day test, 17 people aged 34 to 54 applied a cream with 1 percent of the solution twice daily ².

In the 28-day test, the brochure reports, "eyebags were reduced in 70% of the volunteers," and two color measures of dark circles rose, "showing a slight lightening effect" ². In the 60-day test, skin elasticity "had a 30% increase after 30 days" ².

A 2017 company release reports a split-face test, one side treated and the other the comparison, in men aged 30 to 65 ¹¹. They applied a cream with 1 percent of the solution on one side and a placebo cream, one without the peptide, on the other, twice daily for 28 days ¹¹. It reports "up to 29.7% reduction" in eye-bag volume at 28 days and gives no participant count ¹¹.

Studied in people, as part of an injectable blend: a 2026 open-label, single-arm study in Turkey enrolled 40 women with a mean age of 40.5 years ⁵. Open-label means that everyone knew what was given, and single-arm means that no group went untreated. Each woman received two sessions, three weeks apart, of an injectable placed under both eyes ⁵. It contained hyaluronic acid, a water-holding molecule of the skin, in its non-cross-linked form, seven amino acids and "the EyeSeryl (acetyl tetrapeptide-5) complex" ⁵.

At three months, lower-eyelid skin thickness on ultrasound had risen from 1.34 to 2.05 millimeters, and 34 of the 40 women said they were satisfied ⁵. The authors write that without a control group the changes "cannot be attributed exclusively to the intervention" ⁵. The product is CE-marked, certified for sale in Europe as a medical device, not a cosmetic ⁵.

A 2025 study of a different injectable gel, holding this peptide, two other peptides, amino acids and hyaluronic acid, enrolled 43 participants for three monthly sessions with no control group ⁶. Patients and investigators rated improvement on a five-point scale, and 3D photographs measured wrinkles and lift ⁶. The paper reports an average lifting vector of 1.6 millimeters and gives no under-eye measure ⁶. The gel's maker supplied the product ⁶.

A 2024 single-center, open-label observational study of the same gel enrolled 28 women aged 25 to 65 for four monthly sessions and names no control group ⁷. The gel's maker supplied the material and, the paper says, played no role in the study design or the writing ⁷. None of the three injectable studies can say what the peptide itself did.

Shown in cells: the 2021 study put a mixture of four cosmetic peptides, acetyl tetrapeptide-5 among them, on human skin fibroblasts, the cells that make collagen, under hydrogen peroxide stress ⁸. The mixture reduced markers of oxidative damage ⁸. That result is the mixture's, not the peptide's ⁸. No independent trial of the ingredient alone was found in any source opened. Nor was a study of it longer than 60 days, or a measurement of how much passes through intact skin.

What are the side effects?

No published irritation or sensitization test of acetyl tetrapeptide-5 was found, sensitization being an allergic reaction on repeat contact, and the maker's brochure reports efficacy only ². The documented adverse events are those of the injectable blends, and belong to the injection and the whole product. In the 2026 study, all 80 treated eyelids had mild injection-site pain, five had swelling and three had bruising ⁵. All resolved without treatment, and there were no serious adverse events over three months ⁵. The authors note that events beyond three months could not be assessed ⁵.

In the 2025 gel study, the only adverse effect reported was mild, transient swelling at the injection sites ⁶. Nothing in these studies speaks to the peptide in a cream.

In sport

Acetyl tetrapeptide-5 is not named on the 2026 Prohibited List of WADA, the World Anti-Doping Agency ¹⁷.

What JumpstartMD offers

JumpstartMD does not prescribe acetyl tetrapeptide-5. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 10, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.